Biosimilars
Clinical Trials
Samsung Bioepis Reports Results of Ontruzant (biosimilar, trastuzumab) in P-III
Shots: The four-year follow-up data is part of the ongoing follow-up study, assessing the cardiac safety and survival outcome of Ontruzant vs Herceptin in a subgroup of patients from P-III […]readmore